Novo Nordisk Stock Faces Challenges Amid Competition and Clinical Setbacks

Despite being a leader in the chronic weight management drug market, Novo Nordisk has seen its stock lose about 68% of value over two years due to competition from Eli Lilly's Zepbound and clinical setbacks with its next-gen medicine CagriSema. The company also faces declining GLP-1 market share and downward revenue guidance for fiscal year 2026.

By Prosper Junior Bakiny · Motley Fool · June 3, 2026, 18:45 UTC

Tickers: $LLY $NVO

Topics: CagriSema GLP-1 market Novo Nordisk Wegovy Zepbound

Read the full article at Motley Fool

More World news

Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC